Literature DB >> 18088451

Change in hearing during 'wait and scan' management of patients with vestibular schwannoma.

S-E Stangerup1, P Caye-Thomasen, M Tos, J Thomsen.   

Abstract

AIM: To evaluate hearing changes during 'wait and scan' management of patients with vestibular schwannoma.
SUBJECTS: Over a 10-year period, 636 patients have prospectively been allocated to 'wait and scan' management, with annual magnetic resonance scanning and audiological examination.
RESULTS: At the time of diagnosis, 334 patients (53 per cent) had good hearing and speech discrimination of better than 70 per cent; at the end of the 10-year observation period, this latter percentage was 31 per cent. In 17 per cent of the patients, speech discrimination at diagnosis was 100 per cent; of these, 88 per cent still had good hearing at the end of the observation period. However, in patients with even a small initial speech discrimination loss, only 55 per cent maintained good hearing at the end of the observation period.
CONCLUSION: After comparing the hearing results of hearing preservation surgery and of radiation therapy with those of 'wait and scan' management, it appears that, in vestibular schwannoma patients with a small tumour and normal speech discrimination, the main indication for active treatment should be established tumour growth.

Entities:  

Mesh:

Year:  2007        PMID: 18088451     DOI: 10.1017/S0022215107001077

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  17 in total

1.  Systematic Review of Hearing Preservation in Observed Vestibular Schwannoma.

Authors:  Martin Reznitsky; Per Cayé-Thomasen
Journal:  J Neurol Surg B Skull Base       Date:  2019-03-01

2.  Hearing Outcomes Reporting in Lateral Skull Base Surgery.

Authors:  Geoffrey C Casazza; Christian A Bowers; Richard K Gurgel
Journal:  J Neurol Surg B Skull Base       Date:  2018-12-05

Review 3.  Guidelines in the management of CNS tumors.

Authors:  Navid Redjal; Andrew S Venteicher; Danielle Dang; Andrew Sloan; Remi A Kessler; Rebecca R Baron; Constantinos G Hadjipanayis; Clark C Chen; Mateo Ziu; Jeffrey J Olson; Brian V Nahed
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

4.  CyberKnife for Treatment of Vestibular Schwannoma: A Meta-analysis.

Authors:  Hossein Mahboubi; Ronald Sahyouni; Omid Moshtaghi; Kent Tadokoro; Yaser Ghavami; Kasra Ziai; Harrison W Lin; Hamid R Djalilian
Journal:  Otolaryngol Head Neck Surg       Date:  2017-04-25       Impact factor: 3.497

5.  Hypofractionated stereotactic radiotherapy of acoustic neuroma: volume changes and hearing results after 89-month median follow-up.

Authors:  Manfred Kranzinger; Franz Zehentmayr; Gerd Fastner; Gerhard Oberascher; Florian Merz; Olaf Nairz; Hassan Rahim; Felix Sedlmayer
Journal:  Strahlenther Onkol       Date:  2014-03-18       Impact factor: 3.621

6.  Hearing in static unilateral vestibular schwannoma declines more than in the contralateral ear.

Authors:  Neel B Patel; Carrie L Nieman; Miriam Redleaf
Journal:  Ann Otol Rhinol Laryngol       Date:  2015-01-13       Impact factor: 1.547

Review 7.  [Vestibular schwannoma - management and microsurgical results].

Authors:  S Rosahl; D Eßer
Journal:  HNO       Date:  2017-05       Impact factor: 1.284

8.  Outcome after translabyrinthine surgery for vestibular schwannomas: report on 1244 patients.

Authors:  Jacob Bertram Springborg; Kåre Fugleholm; Lars Poulsgaard; Per Cayé-Thomasen; Jens Thomsen; Sven-Eric Stangerup
Journal:  J Neurol Surg B Skull Base       Date:  2012-06

9.  Systematic Review of Hearing Preservation After Radiotherapy for Vestibular Schwannoma.

Authors:  Adam R Coughlin; Tyler J Willman; Samuel P Gubbels
Journal:  Otol Neurotol       Date:  2018-03       Impact factor: 2.311

10.  Follow-up assessment of vestibular schwannomas: volume quantification versus two-dimensional measurements.

Authors:  Rick van de Langenberg; Bert Jan de Bondt; Patty J Nelemans; Brigitta G Baumert; Robert J Stokroos
Journal:  Neuroradiology       Date:  2009-05-06       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.